Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 19/20 | 0.54 |
| ▸ | INSR | P06213 | 18/20 | 0.54 |
| ▸ | IGF1R | P08069 | 10/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 3/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.51 |
| ▸ | PLK4 | O00444 | 2/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.49 |
| ▸ | PRKCG | P05129 | 2/20 | 0.49 |
| ▸ | ROS1 | P08922 | 2/20 | 0.49 |
| ▸ | FER | P16591 | 2/20 | 0.49 |
| ▸ | LTK | P29376 | 2/20 | 0.49 |
| ▸ | FRK | P42685 | 2/20 | 0.49 |
| ▸ | MST1R | Q04912 | 2/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.49 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.49 |
| ▸ | WEE1 | P30291 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL590786 | 1.00 | ALK (0.54) | ALKINSRIGF1RHTR6AURKA | |
| SCHEMBL591864 | 0.94 | ALK (0.57) | ALKINSRIGF1RAURKAAURKB | |
| SCHEMBL591863 | 0.94 | ALK (0.57) | ALKINSRIGF1RAURKAAURKB | |
| SCHEMBL590076 | 0.94 | ALK (0.56) | ALKINSRIGF1RHTR6AURKA | |
| SCHEMBL592563 | 0.89 | ALK (0.57) | ALKINSRIGF1RHTR6AURKA | |
| SCHEMBL590061 | 0.89 | ALK (0.58) | ALKINSRIGF1RAURKAAURKB | |
| SCHEMBL591974 | 0.88 | ALK (0.58) | ALKINSRIGF1RHTR6AURKA | |
| SCHEMBL590852 | 0.88 | ALK (0.58) | ALKINSRIGF1RAURKAAURKB | |
| SCHEMBL591399 | 0.88 | ALK (0.67) | ALKINSRIGF1RHTR6AURKA | |
| SCHEMBL3503729 | 0.88 | ALK (0.56) | ALKINSRIGF1RHTR6AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3834827-A1 | N-[5-(3,5-DIFLUOROBENZYL)-1H-INDAZOL-3-YL]-4-(4-METHYL-PIPERAZIN-1-YL)-2-(TETRAHYDRO-2H-PYRAN-4-YLAMINO) BENZAMIDE FOR TREATING PATIENTS WITH ROS1,NTRK1, NTRK2 AND NTRK3 MUTANT CANCER CELLS | Ignyta, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3107541-B1 | COMPOUNDS FOR TREATING PATIENTS WITH ROS1 MUTANT CANCER CELLS | IGNYTA INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10682348-B2 | Molecules for administration to ROS1 mutant cancer cells | IGNYTA, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10561651-B2 | Methods for treating neuroblastoma | IGNYTA, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190282564-A1 | MOLECULES FOR ADMINISTRATION TO ROS1 MUTANT CANCER CELLS | IGNYTA, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10231965-B2 | Molecules for administration to ROS1 mutant cancer cells | IGNYTA, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180333412-A1 | METHODS FOR TREATING NEUROBLASTOMA | IGNYTA, INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-20170007599-A1 | METHODS FOR TREATING NEUROBLASTOMA | IGNYTA, INC. | 2017-01-12 | — | — | US | disclosed |
| EP-3107541-A1 | COMPOUNDS FOR TREATING PATIENTS WITH ROS1 MUTANT CANCER CELLS | Ignyta, Inc. (US) | 2016-12-28 | — | — | EP | disclosed |
| US-20150283132-A1 | MOLECULES FOR ADMINISTRATION TO ROS1 MUTANT CANCER CELLS | IGNYTA, INC. | 2015-10-08 | — | — | US | disclosed |
| WO-2015124697-A1 | COMPOUNDS FOR TREATING PATIENTS WITH ROS1 MUTANT CANCER CELLS | IGNYTA, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| EP-2120932-B1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2014-07-09 | — | — | EP | disclosed |
| US-8114865-B2 | Indazole derivatives as kinase inhibitors for the treatment of cancer | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-14 | — | — | US | disclosed |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-08-05 | — | — | US | disclosed |
| EP-2120932-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Nerviano Medical Sciences S.r.l. (IT) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074749-A9 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008074749-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007599-A1 | METHODS FOR TREATING NEUROBLASTOMA | NEK2, CSNK1G3, AHNAK | ALK 556/4885INSR 668/4885IGF1R 215/4885 |
| US-20150283132-A1 | MOLECULES FOR ADMINISTRATION TO ROS1 MUTANT CANCER CELLS | ROS1, KRAS, NOX1 | ALK 337/4885INSR 303/4885IGF1R 72/4885 |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | MAP3K5, MAP3K19, MAP3K3 | ALK 420/4885INSR 400/4885IGF1R 117/4885 |
| US-10561651-B2 | Methods for treating neuroblastoma | UBTF, CABLES1, WEE2 | ALK 1037/4885INSR 1551/4885IGF1R 299/4885 |
| US-10682348-B2 | Molecules for administration to ROS1 mutant cancer cells | ROS1, KRAS, NOX1 | ALK 337/4885INSR 303/4885IGF1R 72/4885 |
| US-10231965-B2 | Molecules for administration to ROS1 mutant cancer cells | ROS1, KRAS, NOX1 | ALK 337/4885INSR 303/4885IGF1R 72/4885 |
| US-20190282564-A1 | MOLECULES FOR ADMINISTRATION TO ROS1 MUTANT CANCER CELLS | ROS1, KRAS, NOX1 | ALK 337/4885INSR 303/4885IGF1R 72/4885 |
| US-20180333412-A1 | METHODS FOR TREATING NEUROBLASTOMA | UBTF, CABLES1, WEE2 | ALK 1037/4885INSR 1551/4885IGF1R 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.